Management of recurrent nasopharyngeal carcinoma: current perspectives

F Perri, G Della Vittoria Scarpati, F Caponigro, F Ionna, F Longo, S Buonopane, P Muto, M Di Marzo, S Pisconti, R Solla

Research output: Contribution to journalReview articlepeer-review


Nasopharyngeal carcinoma is a rare disease in Western countries. Nevertheless, its incidence in China, Singapore, and other Eastern countries reaches 20 cases per 100,000 people. Being an extremely chemo- and radiosensitive disease, upfront treatment often consists in the association of intensity-modulated radiation therapy and concurrent cisplatin. Unfortunately, about 20% of the patients suffer from a radioresistant disease which recurs after upfront therapy. For these patients, mainly available therapeutic options consist in systemic therapy, in particular poly-chemotherapy. In those showing a single locoregional recurrence, chemotherapy is not considered to be the preferred approach and other different strategies may be employed. Re-irradiation and surgery are strategies that are always used more often, albeit related to high risk of morbidity. Immunotherapy and targeted therapy, such as heavy ions-based re-irradiations, are experimental but very intriguing options.

Original languageEnglish
Pages (from-to)1583-1591
Number of pages9
JournalOncoTargets and Therapy
Publication statusPublished - 2019


Dive into the research topics of 'Management of recurrent nasopharyngeal carcinoma: current perspectives'. Together they form a unique fingerprint.

Cite this